| CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1 J Xu, L Ji, Y Liang, Z Wan, W Zheng, X Song, K Gorshkov, Q Sun, H Lin, ... Signal transduction and targeted therapy 5 (1), 298, 2020 | 319 | 2020 |
| N6-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating β-catenin signaling J Xu, Z Wan, M Tang, Z Lin, S Jiang, L Ji, K Gorshkov, Q Mao, S Xia, ... Molecular cancer 19, 1-16, 2020 | 231 | 2020 |
| The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma S Xia, Y Pan, Y Liang, J Xu, X Cai EBioMedicine 51, 2020 | 227 | 2020 |
| Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer H Shen, B Liu, J Xu, B Zhang, Y Wang, L Shi, X Cai Journal of Hematology & Oncology 14, 1-16, 2021 | 110 | 2021 |
| ELF3 promotes epithelial–mesenchymal transition by protecting ZEB1 from miR-141-3p-mediated silencing in hepatocellular carcinoma L Zheng, M Xu, J Xu, K Wu, Q Fang, Y Liang, S Zhou, D Cen, L Ji, W Han, ... Cell death & disease 9 (3), 387, 2018 | 97 | 2018 |
| UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma J Xu, L Ji, Y Ruan, Z Wan, Z Lin, S Xia, L Tao, J Zheng, L Cai, Y Wang, ... Signal transduction and targeted therapy 6 (1), 190, 2021 | 89 | 2021 |
| Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals L Shi, H Lin, G Li, Y Sun, J Shen, J Xu, C Lin, S Yeh, X Cai, C Chang Cancer letters 373 (1), 45-56, 2016 | 80 | 2016 |
| The miR-367-3p increases sorafenib chemotherapy efficacy to suppress hepatocellular carcinoma metastasis through altering the androgen receptor signals J Xu, H Lin, G Li, Y Sun, J Chen, L Shi, X Cai, C Chang EBioMedicine 12, 55-67, 2016 | 79 | 2016 |
| miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR L Ji, Z Lin, Z Wan, S Xia, S Jiang, D Cen, L Cai, J Xu, X Cai Cell Death & Disease 11 (4), 250, 2020 | 71 | 2020 |
| Intrahepatic cholangiocarcinoma: genomic heterogeneity between eastern and western patients J Cao, J Hu, S Liu, F Meric-Bernstam, R Abdel-Wahab, J Xu, Q Li, M Yan, ... JCO Precision Oncology 4, 557-569, 2020 | 67 | 2020 |
| Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals J Xu, L Zheng, J Chen, Y Sun, H Lin, R Jin, M Tang, X Liang, X Cai Cell death & disease 8 (10), e3095-e3095, 2017 | 63 | 2017 |
| Targeting androgen receptor (AR)→ IL12A signal enhances efficacy of sorafenib plus NK cells immunotherapy to better suppress HCC progression L Shi, H Lin, G Li, RA Jin, J Xu, Y Sun, WL Ma, S Yeh, X Cai, C Chang Molecular cancer therapeutics 15 (4), 731-742, 2016 | 62 | 2016 |
| Extrahepatic cholangiography in near-infrared II window with the clinically approved fluorescence agent indocyanine green: a promising imaging technology for intraoperative … D Wu, D Xue, J Zhou, Y Wang, Z Feng, J Xu, H Lin, J Qian, X Cai Theranostics 10 (8), 3636, 2020 | 58 | 2020 |
| LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription Z Lin, S Xia, Y Liang, L Ji, Y Pan, S Jiang, Z Wan, L Tao, J Chen, C Lin, ... Theranostics 10 (19), 8834, 2020 | 52 | 2020 |
| Preclinical studies using miR‐32‐5p to suppress clear cell renal cell carcinoma metastasis via altering the miR‐32‐5p/TR4/HGF/Met signaling M Wang, Y Sun, J Xu, J Lu, K Wang, DR Yang, G Yang, G Li, C Chang International journal of cancer 143 (1), 100-112, 2018 | 45 | 2018 |
| Comparison on the efficacy and prognosis of different strategies for intrahepatic recurrent hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis J Zheng, J Cai, L Tao, MA Kirih, Z Shen, J Xu, X Liang International Journal of Surgery 83, 196-204, 2020 | 39 | 2020 |
| Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma Y Liang, J Chen, Q Yu, T Ji, B Zhang, J Xu, Y Dai, Y Xie, H Lin, X Liang, ... Cancer Medicine 6 (12), 2787-2795, 2017 | 36 | 2017 |
| Sorafenib with ASC‐J9® synergistically suppresses the HCC progression via altering the pSTAT3‐CCL2/Bcl2 signals J Xu, H Lin, G Li, Y Sun, L Shi, WL Ma, J Chen, X Cai, C Chang International journal of cancer 140 (3), 705-717, 2017 | 29 | 2017 |
| Trends and factors affecting hospitalization costs in patients with inflammatory bowel disease: a two‐center study over the past decade J Xu, M Tang, J Shen Gastroenterology Research and Practice 2013 (1), 267630, 2013 | 26 | 2013 |
| Bulk and single-cell transcriptome profiling reveal extracellular matrix mechanical regulation of lipid metabolism reprograming through YAP/TEAD4/ACADL axis in hepatocellular … J Cai, T Chen, Z Jiang, J Yan, Z Ye, Y Ruan, L Tao, Z Shen, X Liang, ... International journal of biological sciences 19 (7), 2114, 2023 | 24 | 2023 |